Revance Publishes its 2022 Environmental, Social, and Governance (ESG) Report
March 30 2023 - 8:00AM
Business Wire
Revance Therapeutics, Inc. (RVNC), today announced the release
of its 2022 ESG Report, detailing the company’s progress towards
its ESG priorities of innovation and access, workplace culture and
strong corporate governance. The report was guided by the
Sustainability Accounting Standards Board (SASB) framework.
“In 2022, we delivered on our promise to bring meaningful
innovation to the market in order to address unmet patient needs
with the FDA’s approval of the first peptide-formulated,
long-acting neuromodulator, DAXXIFY® for glabellar lines. Our first
product approval underscores our commitment to delivering value to
all of our stakeholders,” said Mark J. Foley, Chief Executive
Officer. “Building on this foundation, I’m proud to share our
second ESG report, which details the progress we’ve made across our
ESG priorities in support of our commitment to make a positive
impact while operating sustainably and responsibly. In particular,
our efforts to invest in our people and to build a diverse and
inclusive culture continue to be a key component of our annual
corporate goals. We look forward to building on these efforts as we
launch DAXXIFY® in aesthetics and prepare for our entry into
therapeutics.”
Revance’s 2022 ESG highlights:
- Completed first ESG materiality assessment and first enterprise
risk management assessment with oversight by the Board.
- Conducted culture assessment across employee base to identify
workplace culture strengths and opportunities and implemented
measures in response to opportunity areas.
- Conducted first pay equity assessment for entire
workforce.
- Expanded diversity and inclusion initiatives encompassing
talent attraction, D&I educational programs, and women in
leadership development programs.
- Achieved 100% of corporate goals related to people and D&I
on which a portion of our annual corporate and executive bonuses
are based.
- Continued to enhance executive compensation by increasing the
emphasis of equity awards and bonuses tied to the achievement of
corporate and performance goals.
- Enhanced disclosures related to the company’s supply chain and
product quality and safety in support of the company’s commercial
growth.
- Enhanced disclosures with the addition of responsible drug
promotion practices to the company’s Code of Business Conduct and
Ethics.
The full report can be found on the company’s sustainability
page, link here.
About Revance
Revance is a biotechnology company setting the new standard in
healthcare with innovative aesthetic and therapeutic offerings that
elevate patient and physician experiences. Revance’s aesthetics
portfolio of expertly created products and services, including
DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA®
Collection of dermal fillers, and OPUL®, the first-of-its-kind
Relational Commerce platform for aesthetic practices, deliver a
differentiated and exclusive offering for the company’s elite
practice partners and their consumers. Revance has also partnered
with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for
injection, which will compete in the existing short-acting
neuromodulator marketplace. Revance’s therapeutics pipeline is
currently focused on muscle movement disorders including evaluating
DAXXIFY® in two debilitating conditions, cervical dystonia and
upper limb spasticity.
Revance is headquartered in Nashville, Tennessee, with
additional office locations in Newark, Pleasanton and Irvine,
California. Learn more at www.Revance.com,
www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on
LinkedIn.
“Revance” and the Revance logo, DAXXIFY®, and OPUL® are
registered trademarks of Revance Therapeutics, Inc. Resilient
Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.
Forward-Looking Statements
Any statements in this press release that are not statements of
historical fact, including statements related to our ESG
priorities; our ability to deliver value to our stakeholders; our
commitment to operating sustainably and responsibly; our people
goals; the commercial launch of DAXXIFY®; our entry into the
therapeutics market; the potential to set a new standard of care;
the potential benefits of our products and services, including
DAXXIFY®, the RHA® Collection of dermal fillers and OPUL®; the
extent to which our products and services are considered innovative
and differentiated; development of a biosimilar to
onabotulinumtoxinA for injection with our partner, Viatris; and our
business strategy, timeline and other goals, plans and prospects,
including our commercialization plans; constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. You should not rely upon forward-looking statements as
predictions of future events. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that the future results, levels of
activity, performance, events, circumstances or achievements
reflected in the forward-looking statements will ever be achieved
or occur.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties relate, but
are not limited to: our ability to obtain funding for our
operations; the timing of capital expenditures; the accuracy of our
estimates regarding expenses, revenues, capital requirements, our
financial performance and the economics of DAXXIFY®, the RHA®
Collection of dermal fillers and OPUL®; the risk of future goodwill
impairment charges; our ability to comply with our debt obligations
and draw on our debt; the impact of the COVID-19 pandemic and other
macroeconomic factors on our manufacturing operations, supply
chain, end user demand for our products and services, the
aesthetics market, commercialization efforts, business operations,
regulatory meetings, inspections and approvals, clinical trials and
other aspects of our business and on the market; our ability to
maintain approval of our products; our ability and the ability of
our partners to manufacture supplies for DAXXIFY® and our drug
product candidates; our ability to acquire supplies of the RHA®
Collection of dermal fillers; the uncertain clinical development
process; our ability to obtain, and the timing relating to,
regulatory submissions and approvals with respect to our drug
product candidates and third-party manufacturers; the risk that
clinical trials may not have an effective design or generate
positive results or that positive results would assure regulatory
approval or commercial success; the applicability of clinical study
results to actual outcomes; the rate and degree of economic
benefit, safety, efficacy, commercial acceptance, market,
competition and/or size and growth potential of DAXXIFY®, the RHA®
Collection of dermal fillers, and our drug product candidates, if
approved; our ability to successfully commercialize DAXXIFY® and to
continue to successfully commercialize the RHA® Collection of
dermal fillers and OPUL®; the timing and cost of commercialization
activities; the proper training and administration of our products
by physicians and medical staff; our ability to expand sales and
marketing capabilities; the status of commercial collaborations;
changes in and failures to comply with laws and regulations; our
ability to effectively manage our expanded operations in connection
with the acquisition of Hint, Inc; the rate and degree of
commercial acceptance, market, competition and growth potential of
OPUL®; the profitability of and our ability to scale OPUL®, the
features and functionalities and benefits to practices and patients
of OPUL®; interruptions or performance problems associated with
OPUL®; our ability to continue obtaining and maintaining
intellectual property protection for our products; the cost and our
ability to defend ourselves in product liability, intellectual
property, class action or other lawsuits; the volatility of our
stock price; and other risks. Detailed information regarding
factors that may cause actual results to differ materially from the
results expressed or implied by statements in this press release
may be found in our periodic filings with the Securities and
Exchange Commission (SEC), including factors described in the
section entitled "Risks Factors" on our Form 10-K, which was filed
with the SEC on February 28, 2023. The forward-looking statements
in this press release speak only as of the date hereof. We disclaim
any obligation to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230330005284/en/
Investors Revance Therapeutics, Inc.: Jessica Serra,
510-279-6886 Jessica.serra@revance.com or Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620 laurence@gilmartinir.com
Media Revance Therapeutics, Inc.: Sara J. Fahy,
949-887-4476 sfahy@revance.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Jul 2023 to Jul 2024